Share
.webp)
.webp)
.webp)
.webp)
Matthew Shields
Teva Pharmaceutical Industries has announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO).
Mr. Shields will succeed Eric Drapé, who is stepping down after more than 11 years with the company, including four years as EVP of Global Operations. Shields will join Teva’s Executive Leadership Team and report directly to President and CEO Richard Francis, based at Teva’s U.S. headquarters in Parsippany, NJ.
With over 25 years of experience in the biopharmaceutical and animal health sectors, Mr. Shields brings deep expertise in manufacturing and supply chain processes. Most recently, he was Senior Vice President for Animal Health Manufacturing at Merck, where he led global manufacturing and supply chain efforts. Prior to Merck, he held senior leadership roles at Sanofi and Amgen, overseeing operational excellence and process development.
“We are excited to welcome a leader of Matthew’s caliber to Teva’s executive team,” said Richard Francis, President and CEO of Teva. “His vast experience in health operations aligns perfectly with our mission to serve patients and healthcare systems globally. Matthew is well-suited to lead our TGO organization into the next phase of our ‘Pivot to Growth’ strategy.”
Reflecting on Eric Drapé’s tenure, Francis added: “Eric has played an instrumental role in strengthening our operations network, standardizing processes, and improving operational efficiency. We thank him for his valuable contributions and wish him the best in his next chapter.”
Commenting on his new role, Mr. Shields said, “Teva’s ‘Pivot to Growth’ strategy is already showing great potential, and I am honored to take on this critical role. I look forward to collaborating with the talented team at Teva Global Operations and contributing to the company’s purpose of delivering vital medicines to patients worldwide.”
